Clonal Evolution in Myelodysplasia and Acute Myeloid Leukaemia following Azacitidine

阿扎胞苷后骨髓增生异常和急性髓系白血病的克隆进化

• 批准号: nhmrc : 1128984
• 负责人: A/Pr Sarah-Jane Dawson
• 金额: $ 58.35万
• 依托单位: The University of Melbourne
• 依托单位国家: 澳大利亚
• 项目类别: Project Grants
• 财政年份: 2017
• 资助国家: 澳大利亚
• 起止时间: 2017-01-01 至 2020-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/clonal-evolution-myelodysplasia-following-azacitidine/948328
• 关键词: Clonal; Evolution; Myelodysplasia; Acute; Myeloid

The myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) represent a spectrum of clinically heterogeneous malignancies that remain incurable in the vast majority of patients. Whilst the DNA mutations underpinning the initiation/maintenance of these malignancies are largely known we have little insight into how these mutations alter response to therapy. Using a range of sophisticated cutting edge technologies we will study how these DNA mutations evolve over the course of treatment.

骨髓增生异常综合征（MDS）和急性髓性白血病（AML）代表了一系列临床异质性恶性肿瘤，在绝大多数患者中仍然无法治愈。虽然这些恶性肿瘤的发生/维持的DNA突变基本上是已知的，但我们对这些突变如何改变对治疗的反应知之甚少。使用一系列复杂的尖端技术，我们将研究这些DNA突变如何在治疗过程中演变。